BC Extra | Oct 30, 2019
Company News

Amgen narrows neuro focus to inflammation

Despite early success for Amgen’s first marketed neurology product, the company will exit research and early development for neuroscience, narrowing its focus to neuroinflammation. “To compete effectively, we need to make investments in the areas...
BC Extra | Oct 1, 2019
Company News

Biogen turns to R&D vet as Ehlers exits

While Biogen head of R&D Michael Ehlers is departing the biotech to join the VC ranks amid a series of recent clinical disappointments, pipeline additions during his tenure could start to bear fruit over the...
BC Extra | Sep 14, 2019
Clinical News

One amyloid candidate left for Biogen, Eisai after axing BACE trials

Despite ending two Phase III trials of BACE inhibitor elenbecestat Friday, Biogen and Eisai have not walked away from the amyloid hypothesis of Alzheimer’s disease. The partners' Phase III trial of anti-amyloid mAb BAN2401 forges...
BC Extra | Jul 12, 2019
Clinical News

Amyloid hypothesis takes first hit in an Alzheimer’s prevention setting

With Novartis and Amgen’s decision to halt a pair of trials in presymptomatic Alzheimer’s patients Thursday, what was widely considered the only setting left for the amyloid hypothesis in the disease took a blow. Amyloid-lowering...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Extra | May 10, 2019
Financial News

New Eisai venture arm to focus on digital tech, dementia, cancer

As Eisai looks to digital technologies for dementia drug discovery, the Japanese pharma’s newly launched venture arm has made its first investment and backed Tokyo-based digital healthcare company Allm. Eisai Co. Ltd. (Tokyo:4523) said the...
BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
BC Extra | Apr 24, 2019
Company News

Biogen reiterates late-stage M&A priority as it calls off planned aducanumab trial

As it contemplates exiting β-amyloid programs, Biogen is prioritizing late-stage M&A to shore up its pipeline and preparing to deliver near-term Phase II readouts from a stable of other non-Alzheimer's disease candidates. The bellwether also...
BC Week In Review | Nov 9, 2018
Clinical News

Lilly drops BACE inhibitors for Alzheimer’s

Eli Lilly and Co. (NYSE:LLY) discontinued the combination arm evaluating anti-β-amyloid mAb LY3002813 plus BACE inhibitor LY3202626 in the Phase II TRAILBLAZER-ALZ trial to treat Alzheimer's disease. Spokesperson Nicole Herbert told BioCentury that Lilly has...
BC Week In Review | Jun 15, 2018
Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials...
Items per page:
1 - 10 of 54